Morning Trend | BOAN BIOTECH's trading volume is sluggish, and the rebound window has not appeared under cautious capital?

BOAN BIOTECH (6955.HK) fell into a correction again yesterday, with a sluggish market and weak willingness from major players to enter. Technical indicators show that short-term pressure remains, with short- to medium-term moving averages declining, and the MACD weak structure continuing. Active funds have not dared to enter significantly, maintaining low trading volume throughout the day. The entire biotechnology sector is significantly affected by market confidence and liquidity, with cross-border funds being cautious, increasing selling pressure. Industry news is sparse, with no substantial catalysts; a recent research report from a brokerage downgraded the growth expectations for innovative drug companies in 2025, putting pressure on the biotech sector as a whole. BOAN BIOTECH itself has no highlights, and institutions prefer to wait and see. The market is focused on whether the previous low support is effective; if there are sudden favorable policies or unusual movements from industry leaders, it may drive a rebound. However, the overall atmosphere of caution currently dominates the trading community. Short-term operational risks remain, and position management and timing strategies are the primary focus. The low trading volume and weak subjective funding mean that the short-term rebound window has not yet been established. Future attention should be paid to signs of marginal improvement in funding and the realization of industry catalytic events